

## **Pharmacy Drug Policy Checklist**

POLICY NAME Xolremdi (mavorixafor) POLICY #

## Criteria

Coverage Criteria	
	1.1 Diagnosis of WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome confirmed by pathogenic and or likely pathogenic variants in the CXCR4 gene
	<b>1.2</b> Documentation of symptoms and complications associated with WHIM syndrome (e.g. warts, hypogammaglobulinemia, recurrent infections, and myelokathexis)
	1.3 Documentation of member's baseline absolute lymphocyte count (ALC) and number of infections experienced within the last year
	1.4 Age 12 years or older
	1.5 Prescribed by or in consultation with an immunologist, geneticist, or hematologist
	<b>1.6</b> Baseline absolute neutrophil count (ANC) is $\leq$ 400 cells/ $\mu$ L
	1.7 Review of clinical documentation and confirming that patient has met all of the above requirements for treatment completed by both a pharmacist and medical director